{'fraction_non_alphanumeric': 0.0546875, 'fraction_numerical': 0.0390625, 'mean_word_length': 4.573913043478261, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The ‘endoscope‐i’: a mobile solution for endoscopy in otolaryngology

Thirty seven patients treated for H&N carcinoma, dying as inpatients between 2005 and 2010, were identified. Four (11%) were cared for by the H&N team. All MCCDs were completed by doctors at CT Year 2 or below. Of the 37 cases, 17 (46%) had proven locoregional recurrence or metastases from H&N primary. In 8 (47%) of these cases, the carcinoma was not mentioned on the MCCD. Twenty (54%) had no evidence of recurrence or metastases at last clinic review. Seven (35%) cases mentioned the carcinoma on the MCCD without evidence that it contributed to the death (Table 1).